Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan

  • Technology appraisal guidance
  • TA45
  • Published: 

This guidance has been updated and replaced by NICE technology appraisal guidance 91.